MED-X, INC.

Netcapital

Agape ATP

PicoCELA

Tradr 2X Long QBTS Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Akanda

Everbright Digital

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

MXRX

MediXall Group (MDXL) has announced a delay in filing its Form 10-K for the fiscal year ending December 31, 2025, citing difficulties in obtaining necessary financial information. The company expects to file within the 15-day extension period allowed under Form 12b-25 rules. MediXall is also working on overdue Form 10-Q filings for the quarters ended March 31, June 30, and September 30, 2025. The CFO, Travis Jackson, signed the notification, emphasizing management's responsibility for the filings' timing and accuracy. The company does not anticipate significant changes in its operational results compared to the previous fiscal year.

Tip Ranks

iShares Global Healthcare

Pediatrix Medical

iShares US Healthcare Providers

SPDR S&P Health

VG Health

Health Care Select Sector SPDR

MediXall Group Delays Annual SEC Filing

VIRX

ValiRx updates registered office as it advances oncology and women’s health focus

Viracta Therapeutics

ValiRx updates registered office as it advances oncology and women’s health focus

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

MEDX

MedX Seeks Extension to Complete Convertible Note Financing for Teledermatology Expansion

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

SPDR S&P Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Horizon Kinetics Medical ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

MedX Seeks Extension to Complete Convertible Note Financing for Teledermatology Expansion

GDRX

BoomRx, a leading pharmaceutical technology platform, has achieved over $15.5 million in net order revenue and processed more than 77,000 orders since its launch in July 2025. The platform is now used by over 1,750 clinics nationwide, averaging 8,000 orders monthly with a 2.4% refund rate. BoomRx streamlines prescription sourcing and fulfillment, integrating with clinics' EMRs to enhance operational efficiency. The company will showcase its technology at the A4M Longevity Springfest 2026 in West Palm Beach, Florida.

prnewswire

GoodRx

08:50 ETBoomRx Surpasses $15.5 Million in Net Order Revenue and 77,000+ Processed Orders in First Eight Months

MED-X, INC.(MXRX.US)

MediXall Group Delays Annual SEC Filing

ValiRx updates registered office as it advances oncology and women’s health focus

ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

MedX Seeks Extension to Complete Convertible Note Financing for Teledermatology Expansion

08:50 ETBoomRx Surpasses $15.5 Million in Net Order Revenue and 77,000+ Processed Orders in First Eight Months